GRADIAN DIAGNOSTICS

Gradian was formed in 2018 to unlock value in Molzym GmbH & Co. KG (“Molzym”), a leader in the development of innovative solutions in biological research and diagnosis of infectious diseases. Our commitment to the society is to keep on contributing to a safer and healthier world.

DIVISIONS

Healthcare providers and governments are placing increasing emphasis on early detection to improve people’s lives and reduce healthcare costs. Gradian Diagnostics supports companies developing exciting new technologies, from point-of-care testing to lab automation.

We provide advanced technologies for the sensitive detection, precise identification and thorough analysis of bacteria and fungi by molecular methods.

The fast identification of pathogens is essential for best management of serious infections. Based on its unique disruptive technology, Molzym is developing and optimizing fast and reliable broad-range diagnostic solutions in just one protocol, to identify microorganisms with leading high quality reagents.

SEPSIS, AND OVERCHARGED RESPONSE BY THE BODY TO INFECTION, IS ASSOCIATED WITH ONE IN FIVE DEATHS WORLDWIDE

ABOUT US

Gradian was born from the idea that many emerging medical technology companies would benefit, not only from financial, but also managerial, sales and marketing skills to fully reveal their potential.  Molzym is Gradian´s first acquisition.

Gabriel Tirouflet (CEO of Gradian and Molzym) “After 6 months of intensive work with the operating team, I´m convinced Molzym will play a great role in current Healthcare system changes, bringing a complement to culture with molecular diagnostic capacity, towards precision medicine.

Jakob Glatz (Chairman of the Board) “We’re very proud of Molzym team’s mindset, which contributes to a new era of our global Healthcare systems, especially in those challenging times. The change of Board clearly emphasizes the reinforcing of the company strategy, fully dedicated to long-term growth and sustainability. Company has already restructured and set-up innovative solutions with one common goal: bring Molzym solutions for microbial molecular diagnostics at the disposal of any laboratories worldwide, for improved patient care. The Board is glad to bring its expertise in finance and management to lead Molzym life-changing technology to its next level of success.” 

OUR MISSION

Contribute to a safer and healthier world by providing patients with innovative and high-quality relevant in vitro Diagnostic solutions.

OUR VISION

Become Global Leader in Molecular Diagnostics for microbial identification and resistance testing.

  OUR VALUES

Gradian Diagnostics invests time and effort sourcing companies and leverages its financial expertise and network to accompany portfolio companies achieve their goals.

NEWS & PAPERS

Discover Molzym´s unique technology and product portfolio through its 2.30 minute corporate video

STATISTICS

When time is of the essence
0 %
PATIENTS

recieves inappropriate antimicrobial therapy

0 Bn
ESTIMATED YEARLY

healthcare and productivity costs in the U.S. due to antibiotic resistance

0 %
MORE DEATHS

caused by SEPSIS which could have been prevented with rapid diagnosis and treatment

0 M
LIVES

Will be at risk per year by 2050 due to increase in drug-resistant infections

0 %
INCREASE

In mortality for a 6 hour delay in appropriate therapy

0 M
INCIDENCES

Of sepsis Worldwide per year

INVEST IN GRADIAN

Gradian is a Delaware based corporation with proven experience on the healthcare & diagnose market. Our primary goal is to maximize value for all of our stockholders by consummating an initial public offering for Gradian on a US public market. 

You can apply for our research and market documentation to get further information about our investment opportunities and stocks position.

Our Business Model

Molzym sells or leases SelectNATMplus automation device, test kits for routine diagnostics and other research products.

Division

Product Offering

Product Offering

MOLECULAR
DIAGNOSTICS (MDx)

LIFE SCIENCES

Our Business Model

Molzym sells or leases SelectNATMplus automation device, test kits for routine diagnostics and other research products.

Division

MOLECULAR
DIAGNOSTICS (MDx)

Product Offering

Division

LIFE SCIENCES

Product Offering

Market Opportunity

Molzym targets the market for rapid bacterial and fungal identification (ID) and antibiotic resistance testing

Total Addressable Market

Targeting large hospital (500 + beds) and labs, Molzym potential is about 5,000 instrument placements globally.

Total Annual Recurring Revenue (ARR)

Based on sepsis, acute infections and false negative blood culture, Molzym´s market counts with over 50m diagnostic tests every year.

CONTACT

2020 © Gradian Diagnostics. All rights reserved